Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer
Received 14 October 2019
Accepted for publication 29 January 2020
Published 26 February 2020 Volume 2020:12 Pages 1419—1426
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Xenia Elena Bacinschi,1,2 Rodica Maricela Anghel,1,2 Paula Iuliana Toma,3 Inga Safta,4 Alis Ilie,5 Silvia Mihaela Ilie6
1Department of Oncology-Radiotherapy, Institute of Oncology Prof Dr Alexandru Trestioreanu, Bucharest, Romania; 2University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; 3Department of Chemotherapy, OncoFort Clinic, Bucharest, Romania; 4Department of Medical Oncology, Antoine Lacassagne Cancer Center, Nice, France; 5Cancer Biology Transfer Platform, Georges Francois Leclerc Cancer Center, Dijon, France; 6Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France
Correspondence: Inga Safta
Department of Medical Oncology, Antoine Lacassagne Cancer Centre, 33 Avenue de Valombrose, Nice 06189, France
Tel +33 4 92031000
Introduction: Weekly paclitaxel (Ptx) and q3w docetaxel (Dtx) are equivalent in adjuvant breast cancer treatment. Weekly Ptx is better tolerated than q3w Dtx and became the first choice in daily practice, even preoperatively.
Methods: To compare the efficacy and safety of the two regimens, a retrospective analysis was performed in breast cancer patients (pts) referred for neoadjuvant, sequential, taxane-containing chemotherapy to the Institute of Oncology and Oncofort Clinic, Bucharest, between 2008 and 2017.
Results: Forty-seven cases were eligible, median age was 56 years (34– 73 years), mainly stage IIIA–B (53.2%, 25 pts) and ductal invasive (70.2%, 33 pts) of which 24 pts (51%) received q3w Dtx and 23 pts (48.9%) weekly Ptx. The histological response rates were 62.5% (15 pts) and 73.7% (17 pts) (p=0.47), average dose-intensity was 87.7% and 96.7% (p=0.002) and grade III–IV toxicity rate was 12.5% and 13% (p=0.64), respectively. Pathologic response was correlated with immunophenotype, PgR expression, tumor size and backbone chemotherapy (p< 0.05).
Discussion: Our study showed an improved efficacy of taxane’s weekly administration, probably due to a better tolerance and a lower rate of dose-impairing toxicities.
Keywords: operable breast cancer, neo adjuvant chemotherapy, weekly paclitaxel, taxane regimen, pathologic response, toxicities
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]